At AAOS, Should Product Companies Fear Physician Employment?

By some estimates, nearly half of all physicians in certain specialties are no longer independent practitioners, but work within some collaborative arrangement with hospitals as full-time employees. Cardiologists and cardiovascular surgeons are leading the way, but orthopedic surgeons aren't far behind. In a session at this year's American Academy of Orthopedic Surgeons meeting, entitled "Hospitals Buying Surgeon Group Practices: Passing Trend or New Paradigm?," surgeons, hospital executives, and consultants offered their thoughts as to where this trend might lead.

By some estimates, nearly half of all physicians in certain specialties are no longer independent practitioners, but have sold their practices and/or work within some collaborative arrangement with hospitals as full-time employees. Cardiologists and cardiovascular surgeons are leading the way, but orthopedic surgeons aren't far behind.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo

Podcast: Ochre Bio’s Approach To Precision Medicine In Liver Treatment

 
• By 

Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.

Richard DiMarchi On The GLP-1 Revolution: An Overnight Success After 40 Years

 

As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.

Rising Leaders 2025: João Ribas On Building At The Intersection Of Science And Business

 
• By 

João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.